Results 241 to 250 of about 21,074 (263)

Enhancing Incretin Action for the Treatment of Type 2 Diabetes

Diabetes Care, 2003
Drucker Daniel J, D J Drucker
exaly  

Incretin therapies: highlighting common features and differences in the modes of action of glucagon‐like peptide‐1 receptor agonists and dipeptidyl peptidase‐4 inhibitors

Diabetes, Obesity and Metabolism, 2016
Michael Albrecht Nauck
exaly  

Incretin drugs as modulators of atherosclerosis

Atherosclerosis, 2018
Enrique Gallego-Colon, Wojciech Wojakowski, Tomasz Francuz   +2 more
exaly  

New developments in the incretin concept

Diabetologia, 1985
Ebert R, Creutzfeldt W
exaly  

Comparison of incretin immunoassays with or without plasma extraction: Incretin secretion in Japanese patients with type 2 diabetes

Journal of Diabetes Investigation, 2012
Nobuya Inagaki, Yutaka Seino, Daisuke Yabe   +2 more
exaly  

Incretin dysfunction in type 2 diabetes: Clinical impact and future perspectives

Diabetes and Metabolism, 2013
Bo Ahren
exaly  

[Incretin].

Nihon rinsho. Japanese journal of clinical medicine, 2007
Norio, Harada, Yuichiro, Yamada
openaire   +1 more source

Impaired Regulation of the Incretin Effect in Patients with Type 2 Diabetes

Journal of Clinical Endocrinology and Metabolism, 2011
Jens Juul Holst, Tina VILSBØLL, Filip K Knop   +2 more
exaly  

Incretin-based therapy: how do incretin mimetics and DPP-4 inhibitors fit into treatment algorithms for type 2 diabetic patients?

Best Practice and Research in Clinical Endocrinology and Metabolism, 2009
Ulf Smith
exaly  

The incretin system: glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors in type 2 diabetes

Lancet, The, 2006
Michael Albrecht Nauck
exaly